Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB) assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBFree Report) in a report released on Friday. The brokerage issued a sell rating on the stock.

Navidea Biopharmaceuticals Trading Down 5.9 %

Shares of NAVB opened at $0.04 on Friday. The firm has a market cap of $3.50 million, a PE ratio of -0.58 and a beta of 1.15. The firm has a fifty day simple moving average of $0.05 and a two-hundred day simple moving average of $0.07. Navidea Biopharmaceuticals has a 1-year low of $0.02 and a 1-year high of $0.34.

Navidea Biopharmaceuticals (NYSE:NAVBGet Free Report) last issued its earnings results on Tuesday, November 14th. The company reported ($0.02) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. State Street Corp boosted its holdings in shares of Navidea Biopharmaceuticals, Inc. (NYSE:NAVBFree Report) by 1,631.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 412,743 shares of the company’s stock after buying an additional 388,900 shares during the quarter. State Street Corp owned 1.18% of Navidea Biopharmaceuticals worth $38,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.75% of the company’s stock.

About Navidea Biopharmaceuticals

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Recommended Stories

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.